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Abstract 
The study involves comparative quantitative study of eight (8) different brands of Amoxicillin, using UV 
Spectrophotometry and High Performance Liquid Chromatography. All the samples of Amoxicillin tested using 
UV analysis failed the test as all are above the specified range of 90-120% as stated by USP, 2007. Using the 
HPLC analysis, only 3 of the Amoxicillin samples passed the test, Healmox (108.3%), Barbimox (117.5%) and 
Cimoxil (114.98%) while Nemoxil, Amox 500, Cikamox, Climox and Lamox failed the test with 47.17%, 
39.7%, 139.4%, 139.4%, and 74.5% respectively using the standard of 90-120% as specified by USP, 2007. 
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1. Introduction 
 The proliferation of substandard and adulterated pharmaceutical products is a global phenomenon which 
has been of great concern to many countries including Nigeria (Clark, 2002). It was not long ago that the World 
Health Organisation (WHO) rose to the challenge of recommending that all importing countries should protect 
themselves from this menace by under taking sampling products within the distribution network as an important 
element in Quality surveillance (WHO, 1988). 
1.1 Amoxicillin 
Amoxicillin is one of several semi-synthetic derivatives of 6-aminopenicillanic acid (6-APA) developed 
at Beecham in the 1960s. It became available in 1972, and was the second aminopenicillin to reach the market 
(after ampicillin in 1961). Co-amoxiclav became available in 1981 (Raviña E, 2011)  
Simar Preet Kaur et al (2011) carried out a work on Amoxil as a broad spectrum antibiotic and demonstrated that 
Amoxicillin has been found to be more effective against gram positive than gram negative microorganisms and 
demonstrated greater efficacy to penicillin and penicillin V. Moreover, it has been found comparable to other 
antibiotics, e.g. Ampicillin, Azithromycin, Clarithromycin, Cefuroxime and Doxycycline in treatment of various 
infections/ diseases. In the past decade, amoxicillin has been reported to be useful in the management of many 
indications and is used to treat infections of the middle ear (otitis media), tonsils 
 (Inga Odenholt, 2004) carried out a work to compare the pharmacodynamic effects of a 
pharmacokinetically enhanced formulation of amoxicillin 2000mg twice daily, with amoxicillin 875mg twice 
daily, 875mg three times daily and 500mg three times daily against Streptococcus pneumoniae with different 
susceptibility to amoxicillin in an in vitro kinetic model the strains with an MIC of 1 or 2 mg/L were eradicated 
at 24 h when the kinetics of the enhanced formulation were simulated. All the other regimens showed a static 
effect or a slight regrowth (875 mg twice daily) against these strains. Also for the strain with an MIC of 4 mg/L, 
the enhanced formulation was more effective than the other regimens and resulted in no detectable bacteria after 
7 h although regrowth occurred at 24 h. For the strain with the highest MIC (8 mg/L), regrowth was noted for all 
regimens at that time. However, even for this strain, a substantial initial kill was obtained after both doses of the 
enhanced formulation. These findings are in accordance with an earlier study with the enhanced formulation of 
amoxicillin in the same in vitro kinetic model, where standard dosage regimens of amoxicillin gave inferior 
results in comparison with the enhanced formulation against Haemophilus influenza. ( Manimaran, 2010) 
1.2 Structure 
Chemically, it is (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4- 
thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. It may be represented structurally as: 
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The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.45. 
2. Materials and Method 
Eight (8) different brands of Amoxicillin were used for the study 
Pure sample of the drugs were obtained from NAFDAC which serve as standard 
Writing and labeling materials, Measuring cylinder, Beakers, 1000ml volumetric flask, 100ml volumetric flask, 
50ml volumetric flask, Sonicator, Filter paper, Spatula, High performance liquid chromatography set up, UV 
Visible spectrophotometer (Beckman), Analytical weighing balance, Pestle and mortar, Distilled water 
All reagents used were obtained from NAFDAC office, Maiduguri (Sani et al, 2012)1 
2.1 Practical Method 
 The methods employed for the purpose of this study are the UV visible spectrophotometer and high 
performance liquid chromatographic methods. (Sani et al, 2012)2 
2.2 UV Procedure for Amoxicillin (USP, 2007) 
The tablets were assayed spectrophotometrically using the following procedures 
- The average weight of the tablets from each sample was determined by weighing ten(10) tablets and dividing the 
results gotten by eight to obtain the average weight 
- From the value gotten the equivalent weight of each brand was weighed accurately and transferred into 25ml 
volumetric flasks. All the eight samples were labelled using pen and masking tape. 
- To each volumetric flask, 15ml of 0.001M HCl was poured and sonicated for few minutes to dissolve the drug 
molecule and made up to 25ml with the same solvent 
-  The mixture in each flask was mixed well and filtered through a filter paper into clean beakers. 
- The UV spectrophotometer was put at zero by running a base line (200-400) using 0.001M HCl solution as 
blank. 
- The absorbance of each sample was determined at the peak wavelength by putting small amount of the sample 
into a cuvette, and the cuvette was put back into the machine. 
- The same procedure was repeated for the standard using 500mg of the powdered standard and the absorbance 
determined and from which the % content and mg content was determined as: 
% content = Absorbance of sample x 100 
            Absorbance of standard 
 
Mg content = % content x Manufactures claim 
              100 
2.3 HPLC Procedure for Amoxicillin (USP, 2007) 
Diluents – Dissolve 13.6g of monobasic potassium phosphate in 2000ml of water and adjust with a 45% 
(w/w) solution of potassium hydroxide to a PH of 5.0 + 0.1 
Mobile phase – prepare a suitable mixture of diluents  and acetonitrile (96:4). Make adjustments if 
necessary. Decrease the acetonitrle concentration to increase retention time of amoxicillin 
Standards’ preparation – Quantitatively dissolve an accurate weighed quantity of USP amoxicillin s in 
diluents to obtain a solution having a known concentration of about 1.2g per ml. use this solution within 6hours 
Assay Preparation – transfer about 240mg of Amoxicillin accurately weighed to a 200ml volumetric 
flask, dissolve in and dilute with diluents to volume and mix. Use this solution within 6 hours 
Chromatographic System – The liquid chromatography is equipped with a 230nm detector and a 4mm x 
25cm column that contains packing L1 and standard preparation and record the peak response as directed for 
procedure. The capacity factor K is between 1.1 and 2.8, the column efficiency is not less than 1700 theoretical 
plates, the failing factor is not more than 2.5 and the relative standard deviation for the replicate inventory is not 
more than 2.03 
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Procedure – separately inject equal volumes (about 10µl) of the standards preparation and the assay 
preparation into the chromatograph, record the chromatograms and measure the response for the major peaks. 
Amoxicillin Rs in the standard preparation P is the stated amoxicillin content in µg per mg (Sani et al, 2012)3  
 
3. Results 
Table :1 name and code for the samples 
Brand Name Brand Code 
Healmox L 
Climox M 
Barbimox N 
Cimoxil O 
Lamox P 
Nemoxil I 
Amox 500 J 
Cikamox K 
 
The data below show the result of UV spectrophotometer which is used to calculate the percentage and 
milligram content of the following drugs. 
The results are as follows: 
 
3.1 UV FOR AMOXICILLIN 
I 
%content = 225.87 x 100 = 140.7% 
        160.50 
     Mg content = 140.7  x 500 = 703.5mg 
               100 
 
J 
%content = 247.28 x 100 = 154.1% 
       160.50 
      Mg content = 154.1  x 500 = 770.5mg 
                100 
 
K 
%content = 344.06 x 100 = 214.4% 
       160.50 
     Mg content = 214.4  x 500 = 1072mg 
              100 
 
L 
%content = 336.64 x 100 = 240.9% 
         160.50 
      Mg content = 240.9  x 500 = 1204.5mg 
                100 
 
M 
%content = 370.72 x 100 = 212.3% 
      160.50 
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      Mg content = 212.3  x 500 = 1061.5mg 
               100 
 
N 
%content = 319.64 x 100 = 199.2% 
     160.50 
      Mg content = 199.2  x 500 = 996mg 
                     100 
 
O 
%content = 319.38 x 100 = 198.9% 
       160.50 
      Mg content = 198.9  x 500 = 994.5mg 
                100 
 
P 
%content = 327.63 x 100 = 204.1% 
       160.50 
      Mg content = 204.1  x 500 = 1020.5mg 
                 100 
 
Table 2: percentage content and mg content of amoxicillin (500mg) 
Sample                             %content                                          mg content 
I                                         140.7                                                     703.5 
J                                         154.1                                                     770.5 
K                                        214.4                                                    1072 
L                                         240.9                                                    1204.5 
M                                        212.37                                                 1061.5 
N                                        199.2                                                    996 
O                                        198.9                                                    994.5 
P                                         204                                                       10250 
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3.2 HPLC for Amoxicilline 
Figure 1: 
Analyst:  manager  
Sample ID:  AMOXICILLIN STD 110413   Vial:  200   Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.393 52548746 99.853 IV 
  4.403 77123 0.147 VI 
     
Totals     
  52625869 100.000  
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Figure 2: 
Analyst:  manager  
Sample ID:  P 110413    Vial:  180    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.380 39184524 99.897 IV 
  4.360 40246 0.103 VB 
     
Totals     
  39224770 100.000  
 
% content = 39184524 x 100 = 74.57% 
           52548746 
 
Mg content = 74.57 x 500 = 372.85mg 
         100 
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Figure 3: 
Analyst:  manager  
Sample ID:  I 110413    Vial:  190    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.387 24786855 99.893 IV 
  4.363 25039 0.101 VV 
  4.710 1398 0.006 VB 
     
Totals     
  24813292 100.000  
 
% content = 24786855 x 100 = 47.17% 
       52548746 
 
Mg content = 47.17 x 500 = 235.85mg 
          100 
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Figure 4: 
Analyst:  manager  
Sample ID:  N 120413    Vial:  120    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.457 61745084 99.804 IV 
  3.967 85156 0.138 VV 
  4.593 36326 0.059 VE 
     
Totals     
  61866566 100.000  
 
% content = 61745084 x 100 = 117.5% 
        52548746 
 
Mg content = 117.5 x 500 = 587.5mg 
          100 
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Figure 5: 
Analyst:  manager  
Sample ID:  J 120413    Vial:  150    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.450 20912659 100.000 II 
     
Totals     
  20912659 100.000  
 
% content = 20912659 x 100 = 39.79% 
       52548746 
 
Mg content = 39.79 x 500 = 198.95mg 
        100 
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Figure 6: 
Analyst:  manager  
Sample ID:  O 120413    Vial:  170    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.447 60420081 99.916 IV 
  4.560 50571 0.084 VE 
     
Totals     
  60470652 100.000  
 
% content = 60420081 x 100 = 114.98% 
       52548746 
 
Mg content = 114.98 x 500 = 574.9mg 
         100 
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Figure 7: 
Analyst:  manager  
Sample ID:  K 120413    Vial:  140    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.453 32113216 99.924 IV 
  4.583 24544 0.076 VE 
     
Totals     
  32137760 100.000  
% content = 32113216 x 100 = 61% 
       52548746 
 
Mg content = 61 x 500 = 305mg 
      100 
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Figure 8: 
Analyst:  manager  
Sample ID:  L 120413    Vial:  130    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  2.463 56901408 99.858 IV 
  4.613 80775 0.142 VE 
     
Totals     
  56982183 100.000  
% content = 56901408 x 100 = 108.28% 
        52548746 
 
Mg content = 108.28 x 500 = 541.4mg 
          100 
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Figure 9: 
Analyst:  manager  
Sample ID:  M 120413    Vial:  160    Injection Volume:  20  
Minutes
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  0.157 54210 0.073 BB 
  1.053 2341 0.003 BV 
  1.177 192729 0.261 VV 
  1.397 27128 0.037 VB 
  1.683 110458 0.150 BV 
  1.933 129313 0.175 VV 
  2.450 73262004 99.191 VV 
  4.567 81262 0.110 VE 
     
Totals     
  73859445 100.000  
 
% content = 73262004 x 100 = 139.4% 
       52548746 
 
Mg content = 74.57 x 500 = 697mg 
          100 
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Table3: percentage content and mg content of amoxicillin 500mg using hplc analysis. 
Sample                             %content                                          mg content 
I                                         47.17                                                  235.85 
J                                        39.79                                                  198.95 
K                                         61                                                       305                                    
L                                        108.28                                                541.4 
M                                       139.4                                                  697 
N                                        117.5                                                  587.5 
O                                        114.98                                                574.9 
P                                        74.57                                                  372.85 
 
4. Discussion  
As stated by united state pharmacopoeia (USP 2007 VOLUME II), an amoxicillin capsule should contain not 
less than 90% and not more 120% of labeled amount of amoxicillin. 
 The standard amoxicillin capsule has an absorbance of 160.5.from the results obtained using UV 
spectrophotometer I with percentage content of 140.7%, J 154.1, K 214.4, L 240.9%, M 272.3%, N 199.2%, O 
198.9% and P 204.1%. Many fell above the range specified by the U.S Pharmacopoeia. 
For Amoxicillin, the percentage content of L is 108.3%, O 114.98% and N 117.5% are the only samples that 
passed as compared to the specified limit in the USP, I 47.17%, J 39.7%,K 139.4%, , and P 74.5% failed because 
they contain above or below the specified limit by the USP. 
 
5. Conclusion 
It can be concluded that in the analysis of amoxicillin using HPLC, only three (3) samples passed 
because they are within the specified limit as laid down by B.P and 6 samples failed. Using UV 
spectrophotometry, all the samples failed. 
 
6. Recommendation 
 When a drug taken does not contain the specified amount of active principle, and due to the great 
association between dose and response, the response may not be obtained which may require increase or 
decrease in dose. 
 Considering the toxic effect of amoxicillin, it should be recommended that each batch of the tablet or 
capsules produced by every company undergoes quantitative assay, to ensure that they contain the right amount 
of the active principle as specified by the official books.   
 
References 
British Pharmacopoeia (2008). Volume 111, Her Majesty Stationary Office, London.  pp 2525, 2781, 3013 
Clarke S. (2002). A case study and report presented at the global forum on Pharmaceutical counterfeiting held in 
Geneva. 
Manimaran, V., Mothilal, M., Damodharan, K. and Ruby, M.C. (2010) Enhancemnt  of dissolution rate of 
glibenclamide by solid dispersion technology.  International Journal of Current Pharmaceutical Research. 
2(3): 14-17 
Odenholt I., Cars O., and Lowdin E. (2004) Pharmacodynamic studies of amoxicillin against Streptococcus 
pneumoniae: Comparison of a new pharmacokinectically enhance formulation 2000mg twice daily with standard 
regimens. Journal of Antimicrobial Chemotherapy 54(6): 1062- 1066. 
Ravina, E., (2011). The Evolution of Drug Discovery. Weinheim: Wiley-VCH. p.  262  
Sani Ali. Audu, Alemika Emmanuel. Taiwo, Usman Kauna, Sani Musa,and Ilyas Mohammed (2012)1: 
Comparative Study Of High Performance Liquid Chromatography And Ultraviolet Spectrophotometry Methods 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.4, No.24, 2014 
 
123 
On Different Brands Of Metronidazole Tablets Marketed In Maiduguri Metropolitan Council Of Borno State,  
International research Journal of Pharmacy; 3, 8, Pp 157-164 
Sani Ali. Audu, Alemika Emmanuel. Taiwo, Khalil Osedinese Saidu, Sani Musa, Abdulraheem Rafat. Ojuolape, 
Abdulkareem Sikirat. Sani, Abdulraheem Ramat Bukola. and IlyasMohammed (2012)2: Quantitative Analysis Of 
Ten (10) Different Brands Of Chlorpheniramine Tablet Marketed In Maiduguri Metropolitan Council (MMC), 
Journal of Chemical and Pharmaceutical Research ; 4, 7, Pp 3637-3650 
Sani Ali Audu, Alemika Emmanuel Taiwo, Fatima Ibrahim Waziri, Abdulraheem Rafat Ojuolape, Abdulkareem 
Sikira Sani, Abdulraheem Ramat Bukola, and Ilyas Mohammed (2012)3: Comparative Evaluation Study on 
Different Brands of Lisinopril Tablet Using HPLC and UV Spectrophotometer, Journal of Natural Sciences 
Research 2, 7, Pp 18-25 
Simar, P.K., Rekha, R., and Sanju, N., (2011). Amoxicillin: A broad spectrum  antibiotics. International 
Journal of Pharmacy and Pharmaceutical Science.  3(3): 30-37 
(USP, 2007) http://www.usp.org/azindex 
World Health Organisation (1988). World Health Assembly Resolution entiltled  “Rational use of drugs” WHA 
41.16. 
 
